USA flag logo/image

An Official Website of the United States Government

Optimizing Intravenous Glucose Microdialysis with an Embedded System Controller

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
96026 		Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK085747 		Solicitation Year:
N/A 		Solicitation Topic Code:
NIDDK 		Solicitation Number:
N/A
Small Business Information
INVIVOMON, INC.
155 North Craig St. Suite 190 PITTSBURGH, PA 15213
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Optimizing Intravenous Glucose Microdialysis with an Embedded System Controller
Agency: HHS
Contract: 1R43DK085747-01
Award Amount: $139,406.00
 

Abstract:

DESCRIPTION (provided by applicant): Invivomon, Inc. is a company developing in vivo monitoring technologies that will monitor blood glucose automatically through an intravenous (IV) line. The device will consist of a glucose sensor and a small on-board co mputer that will compensate for measurement errors, provide calibration, and glucose level warnings. With these improvements it will be possible to markedly enhance the accuracy of glucose blood level measurements for tight glucose control (TGC). The long term goal is to develop a 'Smart IV' that can be deployed in any patient requiring an IV and will be programmable to gauge glucose, drug, and metabolite levels (e.g., lactate). Phase I will focus on improving microdialysis probe inaccuracies with glucose m easurements and developing an empirical model that will be uploaded to the embedded system controller. Combining this controller with the intravenous microdialysis probe will make it feasible to achieve Clinical Laboratory Improvement Act (CLIA) standards for glucose measurements (10% error or less) and allow safer management of TGC in the Intensive Care Unit. Specific aims include the development of a system capable of detecting dynamic variations in probe performance and providing an empirical model that will provide a correction factor to glucose values. Clinical studies of patients in the Intensive Care Unit are planned for Phase II. The annual cost savings after implementing TGC protocol is expected to be 2- 3 billion based on the 120,000 critical care beds in the U.S. alone. PUBLIC HEALTH RELEVANCE: Keeping glucose levels within a certain range in hospital settings (such as in the intensive care unit) has been shown to be beneficial by reducing complications and the likelihood of death. Invivomo n Inc. is a company developing monitoring technologies that will track glucose levels in blood for hospital patients with an intravenous (IV) line. The long term goal is to develop a 'Smart IV' that can monitor glucose, drug, and metabolite levels.

Principal Investigator:

George Subrebost

Business Contact:

George L. Subrebost
subrebost@invivomon.com
Small Business Information at Submission:

INVIVOMON, INC.
155 North Craig St. Suite 190 PITTSBURGH, PA 15213

EIN/Tax ID: 126411658
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No